| Autor: |
Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., Kipps, T. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p587-589, 3p |
| Abstrakt: |
B Background: b Zilovertamab (Zilo) is a humanized monoclonal antibody that inhibits the tumor promoting activity of the cancer stem cell receptor, ROR1, which is highly expressed in many hematologic malignancies but not on normal adult tissues. B Safety in MCL and CLL: b The most frequent (>=30%) treatment emergent adverse events (TEAEs) for all MCL & CLL pts on Zilo+Ibr ( I n i = 85) were diarrhea & fatigue (45.9%), contusion (38.8%) and cough (30.6%). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text